| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2007-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f5022daefcde23d377ef0ea4aa2058e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b16dc417339dfa9b5a08bc16c17586f |
| publicationDate |
2009-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-101588801-A |
| titleOfInvention |
Combination of IAP inhibitors and FLT3 inhibitors |
| abstract |
The present invention relates to combinations of IAP inhibitors and FLT3 inhibitors, pharmacological compositions comprising the combination, methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the second mitochondria-derived activator of caspase (Smac) protein to inhibitor of apoptosis (IAPs)(IAP inhibitor) and one or more pharmaceutically active agents and the use of these combinations for the treatment of acute myeloid leukemia; and a commercial package comprising the combination. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109071525-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109071525-A |
| priorityDate |
2006-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |